New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

Lina Polimeni, chief corporate brand officer at Lilly, notes that public perception of the company has historically been ...

After seven months of living and working onboard the International Space Station (ISS), astronauts of NASA's eighth ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

An Eli Lilly official said decades of insulin research and manufacturing ... the second most commonly prescribed medicine to ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...